PriceTargets.com logo

Ondine Biomedical - OBI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 60
  • Forecasted Upside: 207.69%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 19.50 As of 02/7/2023 04:08 AM ET
+0 (0.00%)

This chart shows the closing price for OBI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ondine Biomedical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBI

Analyst Price Target is GBX 60
▲ +207.69% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Ondine Biomedical in the last 3 months. The average price target is GBX 60, with a high forecast of GBX 60 and a low forecast of GBX 60. The average price target represents a 207.69% upside from the last price of GBX 19.50.

This chart shows the closing price for OBI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Ondine Biomedical.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/25/2023Royal Bank of CanadaReiterated RatingOutperformGBX 60
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Ondine Biomedical

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: GBX 19.50
Low: 19.50
High: 19.50

50 Day Range

MA: GBX 20.50
Low: 17
High: 25

52 Week Range

Now: GBX 19.50
Low: 14.97
High: 55

Volume

307 shs

Average Volume

122,342 shs

Market Capitalization

£37.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ondine Biomedical?

The following Wall Street analysts have issued stock ratings on Ondine Biomedical in the last year: Royal Bank of Canada.
View the latest analyst ratings for OBI.

What is the current price target for Ondine Biomedical?

1 Wall Street analysts have set twelve-month price targets for Ondine Biomedical in the last year. Their average twelve-month price target is GBX 60, suggesting a possible upside of 207.7%. Royal Bank of Canada has the highest price target set, predicting OBI will reach GBX 60 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of GBX 60 for Ondine Biomedical in the next year.
View the latest price targets for OBI.

What is the current consensus analyst rating for Ondine Biomedical?

Ondine Biomedical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OBI will outperform the market and that investors should add to their positions of Ondine Biomedical.
View the latest ratings for OBI.

What other companies compete with Ondine Biomedical?

Other companies that are similar to Ondine Biomedical include Destiny Pharma, OKYO Pharma, SkinBioTherapeutics, C4X Discovery and Poolbeg Pharma. Learn More about companies similar to Ondine Biomedical.

How do I contact Ondine Biomedical's investor relations team?

The company's listed phone number is 604-669-0555. The official website for Ondine Biomedical is www.ondinebio.com. Learn More about contacing Ondine Biomedical investor relations.